INVA

Innoviva, Inc.

15.95 USD
+0.04 (+0.28%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Innoviva, Inc. stock is up 1.05% since 30 days ago. The next earnings date is Jul 31, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 15 June’s closed higher than May. 100% of analysts rate it a buy.

About Innoviva, Inc.

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.

  • Cantor Fitzgerald
    Thu Jun 20, 13:37
    buy
    confirm
  • Cantor Fitzgerald
    Tue Jun 18, 08:09
    buy
    initial